Argentina - español - SANI (Asociación de Cooperativas Argentinas)

allignani hnos. - laika - cipermetrina - shampoo sanitizante – envases por 250 ml. - cipermetrina 0,2 g - el shampoo laika está formulado para embellecer el pelo del animal, y a su vez combatir pulgas y garrapatas.sus principales activos son dos piretroides poderosos, d-tetramethrin, que posee un alto poder de volteo, dándole al producto una efectiva acción inmediata; y cyphenothrin, cuya acción se prolonga en el tiempo, dándole a este shampoo una efectiva y prolongada actividad residual. - caninos; felinos

Chile - español - ISPC (Instituto de Salud Pública de Chile)

s.c. johnson & son chile ltda. - d-fenotrina 97% n°cas:26002-80-2;praletrina 93;4% n°cas: 23031-36-9;d-tetrametrina 95;7 n°cas: 7696-12-0 - sin formulas

Chile - español - ISPC (Instituto de Salud Pública de Chile)

s.c. johnson & son chile ltda. - d-fenotrina 97% n°cas:26002-80-2;praletrina 93;4% n°cas: 23031-36-9;d-tetrametrina 95;7%n°cas: 7696-12-0 - sin formulas

España - español - myHealthbox

ecolab -

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

abbott laboratorios s.a. -

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

generis farmacéutica, s.a. - fenitoina sodica - excipientes: alcohol etilico (etanol),propilenglicol,hidroxido de sodio (e-524) - antiepilÉpticos - derivados de la hidantoína - fenitoína

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

kern pharma, s.l. - fenitoina sodica - excipientes: alcohol etilico (etanol),propilenglicol,hidroxido de sodio (e-524) - antiepilÉpticos - derivados de la hidantoína - fenitoína

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

nrim ltd - fenitoina sodica - excipientes: lactosa monohidrato - antiepilÉpticos - derivados de la hidantoína - fenitoína

Unión Europea - español - EMA (European Medicines Agency)

janssen-cilag international nv - darunavir - infecciones por vih - antivirales para uso sistémico - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.

Unión Europea - español - EMA (European Medicines Agency)

mylan pharmaceuticals limited - darunavir - infecciones por vih - antivirales para uso sistémico - darunavir, co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv-1) infection (see section 4. darunavir mylan 75 mg, 150 mg, 300 mg and 600 mg tablets may be used to provide suitable dose regimens (see section 4. 2):para el tratamiento de la infección por vih-1 en tratamiento antirretroviral (art)-experiencia de los pacientes adultos, incluyendo aquellos que han sido altamente pre-tratados. para el tratamiento de la infección por vih-1 en pacientes pediátricos a partir de la edad de 3 años y en menos de 15 kg de peso corporal. en la decisión de iniciar el tratamiento con darunavir coadministrado con dosis bajas de ritonavir, se debe prestar especial consideración a la historia del tratamiento del paciente y de los patrones de mutaciones asociadas con los diferentes agentes. genotypic or phenotypic testing (when available) and treatment history should guide the use of darunavir (see sections 4. 2, 4. 4 y 5. darunavir coadministrado con dosis bajas de ritonavir está indicado en combinación con otros medicamentos antirretrovirales para el tratamiento de pacientes con virus de inmunodeficiencia humana (vih-1) .  darunavir co-administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv-1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg) (see section 4.  darunavir mylan 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv-1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are: antiretroviral therapy (art)-naïve (see section 4.  art-experienced with no darunavir resistance associated mutations (drv-rams) and who have plasma hiv-1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 10⁶/l. en la decisión de iniciar el tratamiento con darunavir en el arte como experiencia de los pacientes, el análisis genotípico deben guiar el uso de darunavir (ver secciones 4. 2, 4. 3, 4. 4 y 5.